|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.930 CNY | +3.13% |
|
-3.10% | -8.63% |
| Market Cap | 4.1B 604M 530M 488M 455M 858M 57.42B 875M 5.87B 2.27B 28.19B 2.27B 2.22B 98.09B | P/E 2024 |
18.1x | P/E 2025 | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.32B 489M 429M 395M 368M 694M 46.45B 708M 4.75B 1.84B 22.8B 1.83B 1.79B 79.34B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.65x |
| Free-Float |
78.69% | Yield 2024 |
4.93% | Yield 2025 | 5.39% |
| 1 day | +3.13% | ||
| 1 week | -3.10% | ||
| Current month | +3.13% | ||
| 1 month | -6.76% | ||
| 3 months | -11.09% | ||
| 6 months | -8.63% | ||
| Current year | -8.63% |
| 1 week | 5.6 |  | 5.99 |
| 1 month | 5.6 | | 6.46 |
| Current year | 5.6 | | 7.19 |
| 1 year | 5.6 | | 8.68 |
| 3 years | 4.94 | | 9 |
| 5 years | 4.94 | | 11.9 |
| 10 years | 4.5 | | 11.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 42 | 23/04/2019 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 54 | 17/05/2017 |
Peng Bo Ren
PRN | Corporate Officer/Principal | 53 | 11/03/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Wu Xian Ren
CHM | Chairman | 66 | 26/05/2005 |
Peng Bo Ren
BRD | Director/Board Member | 53 | 15/05/2014 |
Wei Ren
BRD | Director/Board Member | 42 | 23/04/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.13% | -3.10% | -2.31% | -16.48% | 586M | |
| +0.20% | -0.10% | +11.37% | +77.46% | 47.26B | |
| -1.30% | -0.42% | +49.14% | +102.33% | 35B | |
| -0.59% | +1.65% | -3.27% | +43.52% | 12.52B | |
| -0.31% | -0.27% | +12.05% | +90.24% | 11.74B | |
| +2.99% | -2.72% | +29.46% | +115.95% | 8.67B | |
| +0.58% | +1.59% | +21.20% | +43.94% | 7.05B | |
| -0.84% | +1.67% | +51.89% | -9.13% | 6.9B | |
| -1.92% | -0.80% | +23.27% | +219.81% | 6.58B | |
| +7.24% | +10.32% | -27.74% | +9.65% | 5.23B | |
| Average | +0.92% | +1.38% | +16.51% | +67.73% | 14.15B | |
| Weighted average by Cap. | +0.03% | +0.72% | +22.09% | +81.85% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.69B 395M 347M 319M 298M 561M 37.59B 573M 3.84B 1.49B 18.45B 1.48B 1.45B 64.21B | 2.24B 330M 289M 266M 248M 468M 31.35B 478M 3.2B 1.24B 15.39B 1.24B 1.21B 53.55B |
| Net income | 243M 35.72M 31.36M 28.87M 26.9M 50.73M 3.4B 51.76M 347M 135M 1.67B 134M 131M 5.8B | 320M 47.1M 41.35M 38.06M 35.47M 66.89M 4.48B 68.25M 458M 177M 2.2B 177M 173M 7.65B |
| Net Debt | -483M -71.07M -62.4M -57.44M -53.52M -101M -6.76B -103M -691M -268M -3.32B -267M -261M -11.54B | -784M -115M -101M -93.3M -86.94M -164M -10.98B -167M -1.12B -435M -5.39B -433M -424M -18.75B |
Employees
3,415
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/07/26 | CN¥5.930 | +3.13% | 11,823,460 |
| 30/06/26 | CN¥5.750 | -3.20% | 10,980,770 |
| 29/06/26 | CN¥5.940 | +4.21% | 13,534,002 |
| 26/06/26 | CN¥5.700 | -4.04% | 11,816,002 |
| 25/06/26 | CN¥5.940 | -1.33% | 10,545,084 |
- Stock Market
- Stocks
- 600351 Stock
Select your edition
All financial news and data tailored to specific country editions
